Anti-ADRA2B Polyclonal Antibody for WB and ELISA - P18089

Core Product Specifications and Parameters

Biological Background: Alpha-2B Adrenergic Receptor Function and Localization

• Protein Identity: The Alpha-2B adrenergic receptor (gene ADRA2B; aliases ADRA2L1, ADRA2RL1, Alpha-2BAR) is a G protein-coupled receptor (GPCR) belonging to the rhodopsin-like family. It is encoded by a single human gene and shares homology with other alpha-2 subtypes.
• Core Signaling Mechanism: Upon catecholamine binding, ADRA2B couples to G(i/o) proteins, inhibiting adenylyl cyclase activity, stimulating ERK1/2 phosphorylation, and suppressing voltage-gated calcium channels.
  Related references:
  PMID:11056163 PMID:2164221 PMID:2172775
• Physiological Functions: Plays critical roles in regulating systemic blood pressure, promoting lipolysis in adipose tissue, and modulating insulin secretion from pancreatic beta-cells.
  Related references:
  PMID:2164221
• Pharmacological Profile: The agonist potency rank is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. Antagonist potency: yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol.
  Related references:
  PMID:2164221 PMID:2172775
• Subcellular Localization: The receptor is predominantly located on the plasma membrane, consistent with its role as a cell-surface receptor.
• Structural Features: Contains seven-transmembrane helices, a conserved disulfide bond, and a palmitoylation site. Classified under epilepsy-related genes (UniProt keyword), though direct disease mechanisms require further study. The predicted protein weight is approximately 50 kDa (UniProt: 49954 Da).

Experimental Guidance and Technical Tips

• The immunogen corresponds to the N-terminal 1–100 amino acids of human ADRA2B. For peptide competition assays, a blocking peptide spanning the same region may be employed to confirm specificity.
• In Western blotting, a band around 50 kDa is expected. Use appropriate positive controls (e.g., cell lines expressing ADRA2B) and verify membrane preparation to ensure receptor solubility.
• The antibody is reported to cross-react with mouse and rat ADRA2B; however, validation in the target tissue or cell model is recommended due to potential species-dependent epitope variation.
• For ELISA applications, direct adsorption of the synthetic peptide or native receptor-containing membrane preparations can be considered. Optimal coating conditions (pH, temperature) and blocking steps should be determined empirically.
• Due to the low abundance of GPCRs, enrichment of membrane fractions may improve detection sensitivity in protein lysates.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio empowers diagnostic manufacturers, laboratory developers, and research institutes with a seamless, single-point access to high-quality IVD raw materials, technical expertise, and consultative services—guiding projects from early research to clinical application. The anti-ADRA2B polyclonal antibody serves the GPCR, cardiovascular, and metabolic disease research communities. Beyond this product, CamelBio can supply validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and assist in sourcing raw materials for rare targets—streamlining your diagnostic assay development workflow.